| Patients | Endometrial cancer mortality | ||
---|---|---|---|---|
 | N | Deaths | HR | 95% CI |
Age at diagnosis of endometrial cancera | ||||
   < 55 | 190 | 14 | 1.00 | baseline |
   55 to 64 | 469 | 51 | 1.57 | 0.87, 2.84 |
   65 to 74 | 653 | 87 | 2.13 | 1.21, 3.75 |
   75 to 84 | 445 | 92 | 3.65 | 2.08, 6.43 |
   85 and over | 118 | 33 | 5.69 | 3.03, 10.7 |
   Heterogeneity (4 d.f.) |  |  | P < 0.0001 | |
   Trend (1 d.f.) |  |  | P < 0.0001 | |
FIGO stageb | ||||
   I | 1016 | 64 | 1.00 | baseline |
   II | 132 | 26 | 3.34 | 2.11, 5.28 |
   III/IV | 140 | 67 | 13.1 | 9.25, 18.6 |
   Unknown | 587 | 120 | 2.92 | 2.06, 4.14 |
   Heterogeneity (3 d.f.) |  |  | P < 0.0001 | |
Morphologyc | ||||
   Endometrioidd | 1580 | 162 | 1.00 | baseline |
   Serous or clear celle | 108 | 32 | 2.25 | 1.51, 3.37 |
   Carcinosarcomaf | 108 | 54 | 5.41 | 3.92, 7.45 |
   Sarcomag | 54 | 20 | 3.93 | 2.42, 6.38 |
   Unknown | 25 | 9 | 4.11 | 2.06, 8.14 |
   Heterogeneity (4 d.f.) |  |  | P < 0.0001 | |
All non-endometrioidh | 270 | 106 | 3.75 | 2.88, 4.87 |
Morphology by tamoxifen usec | ||||
   Tamoxifen users: |  |  |  |  |
   - non-endometrioid | 190 | 79 | 3.32 | 2.06, 5.35 |
   -endometrioid | 929 | 105 | 1.00 | baseline |
   Tamoxifen non-user |  |  |  |  |
   - non-endometrioid | 80 | 27 | 3.88 | 2.86, 5.28 |
   -endometrioid | 651 | 57 | 1.00 | baseline |
   Heterogeneity interactionh (1 d.f.) |  |  | P = 0.57 | |
   Morphology unknown: | 25 | 9 |  |  |